A selection of publications from Addiction Neuroethics projects

Identifying cutting edge research in addiction neurobiology

Carter, A., P. Bartlett, et al. (2009). "Scare-mongering and the anticipatory ethics of experimental technologies." American Journal of Bioethics 9(5): 47-48.

Carter, A., B. Capps, et al. (2009). Addiction neurobiology: ethical and social implications. EMCDDA Monograph. Lisbon, European Monitoring Centre for Drugs and Drug Addiction.

Carter, A. and W. D. Hall (2007). "The social implications of neurobiological explanations of resistible compulsions." American Journal of Bioethics 7(1): 15-17.

Carter, A. and W. D. Hall (2010). "The need for more explanatory humility in addiction neurobiology." Addiction 105(5): 790-791.

Hall, W. D. (2006). "Avoiding potential misuses of addiction brain science." Addiction 101(11): 1529-1532.

Hall, W. D., B. Capps, et al. (2008). "The use of depot naltrexone under legal coercion: the case for caution." Addiction 103(12): 1922-1924.

Hall, W. D. and A. Carter (2007). "Debunking alarmist objections to the pharmacological prevention of PTSD." American Journal of Bioethics 7(9): 23-25.

Lubman, D. I., M. Yucel, et al. (2007). "Substance use and the adolescent brain: a toxic combination?" Journal of Psychopharmacology 21(8): 792-794.

Hall, W. D. (2002). "The prospects for immunotherapy in smoking cessation." Lancet 360(9339): 1089-1091

 

Economic and epidemiological monitoring

Degenhardt, L., H. Whiteford, et al. (2009). "Estimating the burden of disease attributable to illicit drug use and mental disorders: what is 'Global Burden of Disease 2005' and why does it matter?" Addiction 104(9): 1466-1471

Gartner, C. E., J. J. Barendregt, et al. (2009). "Multiple genetic tests for susceptibility to smoking do not outperform simple family history." Addiction 104(1): 118-126.

Gartner, C. E., W. D. Hall, et al. (2007). "Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study." Lancet 369(9578): 2010-2014.

Hall, W. and L. Degenhardt (2009). "Adverse health effects of non-medical cannabis use." Lancet 374(9698): 1383-1391.

 

Approach to policy and ethical analysis

Carter, A. and W. Hall (2010). "Beyond the right to injectable heroin." AJOB Neuroscience 1(1): 48 - 49.

Carter, A. and W. D. Hall (2008). "The issue of consent in research that administers drugs of addiction to addicted persons." Accountability in Research 15(4): 209-225.

Gossop, M. and W. Hall (2009). "Clashes between the government and its expert advisers." BMJ 339: 1095-1096.

Grey, W., W. D. Hall, et al. (2007). "Persons and personification." American Journal of Bioethics 7(1): 57-58.

Hall, W. (2010). "What are the policy lessons of National Alcohol Prohibition in the United States, 1920-1933?" Addiction: http://dx.doi.org/10.1111/j.1360-0443.2010.02926.x.

Hall, W. D. (2006). "The regulatory challenges in engineering a safer tipple." Journal of Psychopharmacology 20(3): 321-322.

Hall, W. D., L. Carter, et al. (2003). "Heroin addiction and the capacity for consent: a reply to Charland." Addiction 98(12): 1775-1776.

Hall, W. D., L. Carter, et al. (2003). "Addiction, ethics and scientific freedom." Addiction 98(7): 873-874.

Hall, W. D., L. Carter, et al. (2003). "Addiction, neuroscience and ethics." Addiction 98(7): 867-870.

Hall, W. D., L. Carter, et al. (2004). "Neuroscience research on the addictions: a prospectus for future ethical and policy analysis." Addictive Behaviors 29(7): 1481-1495.

Hall, W. D. and C. Gartner (2009). "Direct-to-consumer genome-wide scans: Astrologicogenomics or simple scams?" American Journal of Bioethics 9(6): 54 - 56.

Hall, W. D., C. E. Gartner, et al. (2008). "The genetics of nicotine addiction liability: ethical and social policy implications." Addiction 103(3): 350-359.           

Hall, W. D., K. L. Morley, et al. (2004). "The prediction of disease risk in genomic medicine: scientific prospects and implications for public policy and ethics." EMBO Reports 5: S22-S26.

Hall, W. D. and R. L. Pacula (2003). Cannabis use and dependence: public health and public policy. Cambridge, Cambridge University Press.

Hall, W. D. (2007). "A research agenda for assessing the potential contribution of genomic medicine to tobacco control." Tobacco Control 16(1): 53-58.

Hall, W. D. (2005). "Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases?" PLoS Medicine 2(9): 860-863.

Morley, K. I., W. D. Hall, et al. (2004). "Genetic screening for susceptibility to depression: can we and should we?" Australian and New Zealand Journal of Psychiatry 38(1-2): 73-80.

Gartner, C. E., W. D. Hall, et al. (2007). "Should the health community promote smokeless tobacco (snus) as a harm reduction measure?" PLoS Medicine 4(7): 1138-1141.

 

Neuroenhancement/Life extension

Hall, W. D. (2004). "Feeling 'better than well': can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods?" EMBO Reports 5(12): 1105-1109.

Lucke, J. C., P. C. Diedrichs, et al. (2009). "Anticipating the anti-ageing pill: Lessons from the history of the oral contraceptive pill and hormone replacement therapy." EMBO Reports 10(2): 108-113.

Lucke, J. C., D. Herbert, et al. (2010). "Anticipating the use of life extension technologies: possible pointers from the adoption of assisted reproductive technologies (Outlook)." EMBO Reports: 10.1038/embor.2010.1048.

Lucke, J. C. and W. D. Hall (2005). "Who wants to live forever?" EMBO Reports 6(2): 98-102.

Partridge, B., W. Hall, et al. (2009). "Mapping community concerns about radical extensions of human life expectancy." American Journal of Bioethics 9(12): 4 - 5.

Partridge, B., M. Underwood, et al. (2009). "Ethical concerns in the community about technologies to extend human life span." American Journal of Bioethics 9(12): 68-76.

 

Other

Gartner, C. E., J. J. Barendregt, et al. (2008). "Five genetic variants associated with prostate cancer (commentary)." New England Journal of Medicine 358(25): 2738-2739; author reply 2741.